Untitled

The U.S. Food and Drug Administration’s (FDA) Division of Drug Information* presents… Educational Webinars for Healthcare Professionals

FDA’s Division of Drug Information in the Center for Drug Evaluation and Research (CDER) sponsors a series of educational webinars targeting the needs of healthcare professionals and students. The webinars cover a broad range of FDA drug regulation and medication safety topics. These focused webinars support FDA’s mission of promoting and protecting public health through interaction and education to strengthen current and future partnerships and relationships with clinicians and researchers.

Home Study CE Webinar Topics include:

• FDA’s Bad Ad Program
• Nitrosamine Impurities in Drugs: What Health Care Professionals Need to Know
• FDA Regulation of Color Additives in Drug Products
• FDA Oncology Center of Excellence’s Project Facilitate: An Overview of the Oncology Expanded Access Program
• Labeling on Drugs@FDA vs. DailyMed
• FDA’s Postmarketing Drug Safety Surveillance System
• An update to the FDA Adverse Event Reporting System (FAERS) Public Dashboard
• Tainted Products Marketed as Dietary Supplements
• Introduction to the Office of Orphan Products Development (OOPD)
• FDA Drug Information Resources and Applicability to Health Care Professionals
• Research Funding Opportunities to Reduce Preventable Harm
• Building Confidence in Generic Narrow Therapeutic Index (NTI) Drugs
• 3D Printing in Drug Development and Emerging Health Care
• Biosimilar and Interchangeable Biological Products: Basic Concepts and Practical Resources
• Drug Shortages: FDA Efforts, Current Challenges and Future Goal

Past Home Study CE Webinar Topics from the Center for Drug Evaluation and Research (CDER) delivered in 2020 include:

• FDA Drug Topics: Role of FDA and ISMP in Preventing Medication Errors – June 30, 2020 (Postponed from March 17, 2020)
• Webinar: CDER SEND Common Issues and Policy Update – June 15, 2020
• FDA Drug Topics: CURE ID: Capturing Clinician’s Experiences Repurposing Drugs to Inform Future Studies in the Era of COVID-19 – June 9, 2020
• FDA’s Bad Ad Program
• Nitrosamine Impurities in Drugs: What Health Care Professionals Need to Know
• Postmarketing Drug Safety Compliance: 2019 Inspection Findings – Apr. 29, 2020
• FDA’s Postmarketing Drug Safety Surveillance System
• CDER SEND Common Issues and Policy Update – March 20, 2020
• Learn About ClinicalTrials.gov Modernization and How to Provide Input – March 2, 2020
• FDA Drug Information Resources and Applicability to Health Care Professionals
• On Demand Webinar: Recent Revisions to the ANDA Prioritization MAPP – Jan. 2020
• Research Funding Opportunities to Reduce Preventable Harm

Target Audience: The target audience for these courses is healthcare professionals, including physicians, physician assistants, nurses, nurse practitioners, pharmacists, and pharmacy technicians. The courses can be taken for informational purposes or for Continuing Education (CE) credit.

Continuing Education: CE credit is available for the FDA’s live and home study webinars. If you are a physician, physician assistant, nurse, pharmacist, or pharmacy technician, refer to the individual webinar listing for complete CME/AAPA/CNE/CPE/CPT/CPH information. Note:  To receive your certificate for CE credit, you must complete the post-test and receive a score of 80% or better and complete an evaluation form. Other users may complete evaluation and print a Certificate of Completion.

*NOTE: This is an industry resource-sponsored webinar. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products, services, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier, product, service, drug, brand or approach.

For questions about content or about technical issues, contact FDA: (855) 543-3784, or (301) 796-3400; Email: DDIWebinars@fda.hhs.gov. Online at http://www.fda.gov/AboutDDI